What the FDA labels say about taking them together
Insulin degludec and octreotide
Insulin degludec's FDA label of July 1, 2022 names octreotide in its drug interactions section; octreotide's label does not name insulin degludec itself but warns about its class (insulin analogs). The insulin degludec label: “… inhibitors, pentoxifylline, pramlintide, salicylates, somatostatin analogs (e.g., octreotide), and sulfonamide antibiotics, GLP-1 receptor agonists, DPP-4 inhibitors, SGLT-2 inhibitors. …”
Check it at the source: the insulin degludec FDA label on DailyMed (effective July 1, 2022, Novo Nordisk Pharma, Inc.); the octreotide FDA label on DailyMed (effective July 22, 2026, Novartis Pharmaceuticals Corporation).
What does the insulin degludec label say about octreotide?
Insulin degludec label, drug interactionsDrugs That May Increase the Risk of Hypoglycemia Drugs: Antidiabetic agents, ACE inhibitors, angiotensin II receptor blocking agents, disopyramide, fibrates, fluoxetine, monoamine oxidase inhibitors, pentoxifylline, pramlintide, salicylates, somatostatin analogs (e.g., octreotide), and sulfonamide antibiotics, GLP-1 receptor agonists, DPP-4 inhibitors, SGLT-2 inhibitors. Intervention: Dosage reductions and increased frequency of glucose monitoring may be required when Insulin Degludec is co-administered with these drugs.
Source: FDA drug label (Insulin Degludec), Novo Nordisk Pharma, Inc., effective July 1, 2022 (SPL set c1be283d-4b1d-4996-b2a7-4488dbff3037), via openFDA; the full label on DailyMed
What does the octreotide label say about insulin degludec?
Octreotide's label does not name insulin degludec itself; it warns about its class (insulin analogs):
Octreotide label, drug interactionsCyclosporine, insulin, oral hypoglycemic agents, beta-blockers, and bromocriptine. ( 7 ) Lutetium Lu 177
Octreotide label, drug interactionsOctreotide inhibits the secretion of insulin and glucagon.
Source: FDA drug label (Sandostatin), Novartis Pharmaceuticals Corporation, effective July 22, 2026 (SPL set 4e2c9856-1836-49f0-9472-4dbeeb408f39), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Insulin degludec | Octreotide | |
|---|---|---|
| Labeled for | Type 2 diabetes, Type 1 diabetes | Diarrhea |
| Boxed warning | No | No |
| Pharmacy cost (NADAC) | $11.39 per mL 100 unit/mL pen | $2.53 per mL 100 mcg/mL vial |
| Shortage now | No current entry | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once